HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of bevacizumab on corneal neovascularization in rabbits.

AbstractPURPOSE:
To determine the efficacy of topical application and subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
METHODS:
Corneal neovascularization was induced with a silk suture of the corneal stroma in 12 rabbits (24 eyes). One week after suturing, four rabbits were treated with topical bevacizumab at 5 mg/mL (group A) and another four rabbits were treated with topical bevacizumab 10 mg/mL (group B) in the right eyes twice a day for two weeks. A subconjunctival injection of bevacizumab 1.25 mg/mL was done in the right eyes of four rabbits (group C). All of the left eyes (12 eyes) were used as controls. The area of corneal neovascularization was measured after one and two weeks, and the concentration of vascular endothelial growth factor (VEGF) in corneal tissue was measured after two weeks.
RESULTS:
The neovascularized area was smaller in all treated groups than in the control group (p<0.001). Upon analysis of the neovascularized area, there was no significant difference between groups A and B. However, the mean neovascularized area of group B was significantly smaller than that of group C after two weeks of treatment (p=0.043). The histologic examination revealed fewer new corneal vessels in all treated groups than the control group. The concentration of VEGF was significantly lower in all treated groups compared to the control group (p<0.01), but no difference was shown between treated groups.
CONCLUSIONS:
Topical and subconjunctival bevacizumab application may be useful in the treatment of corneal neovascularization and further study is necessary.
AuthorsWung-Jae Kim, Hee-Ok Jeong, Sung-Kun Chung
JournalKorean journal of ophthalmology : KJO (Korean J Ophthalmol) Vol. 24 Issue 4 Pg. 230-6 (Aug 2010) ISSN: 2092-9382 [Electronic] Korea (South)
PMID20714387 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ophthalmic Solutions
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Animals
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Cornea (metabolism, pathology)
  • Corneal Neovascularization (drug therapy, metabolism, pathology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Male
  • Ophthalmic Solutions
  • Rabbits
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: